Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program PRINCETON, N.J., March 09, 2026 BUSINESS WIRE Bristol Myers Squibb (NYSE: BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976). In the trial, oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM). Safety findings were consistent with the known profile of mezigdomide and the combination regimen. Patients will continue to be followed for survival and safety. "We are excited by these results, which underscore Bristol Myers Squibb's leadership in treating multiple myeloma and our unwavering commitment to patients living with this persistent and challenging dise
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Tests New Protein Degradation Cancer Drug In Humans [Yahoo! Finance]Yahoo! Finance
- BioIVT to Showcase ADME-Tox and NAMs Expertise at Spring 2026 Industry Events [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026Business Wire
- Don't Miss This 14% Yield And This Pharma Value Stock [Seeking Alpha]Seeking Alpha
BMY
Earnings
- 2/6/26 - Beat
BMY
Sec Filings
- 3/12/26 - Form 4
- 3/12/26 - Form 4
- 3/12/26 - Form 4
- BMY's page on the SEC website